Dr. Theodoros Kelesidis, MD

Dr. Kelesidis practices at Parkland Memorial Hospital in Dallas, Texas, part of Parkland Health.

Dr. Kelesidis' NPI, 1043487317, was assigned on May 14, 2008. Dr. Kelesidis graduated from University of Athens in 2004. Dr. Kelesidis holds Texas license U5140.

Dr. Kelesidis' primary practice is Parkland Memorial Hospital, at 5200 Harry Hines Blvd, Dallas, TX 75235 in Dallas County. The practice phone is (214) 590-8000.

Dr. Kelesidis' primary practice is Parkland Memorial Hospital in Dallas, Texas, part of Parkland Health. Dr. Kelesidis is also affiliated with William P. Clements Jr. University Hospital. The medical group on file is University of Texas Southwestern Medical Center. Dmand AI also links Dr. Kelesidis to 1 more clinical lab and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kelesidis practices, 4 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Kelesidis' primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Kelesidis is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. Kelesidis' licenses on file in 3 states: Texas, California and Massachusetts.

Dmand AI lists hiv/aids and pneumonia among the conditions Dr. Kelesidis treats.

CMS data shows 100 Medicare services from Dr. Kelesidis across 2 procedure codes in 2024, for 67 Medicare patients. Medicare paid $11,075 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 67 Medicare patients who saw Dr. Kelesidis in 2024. The largest group is 65 to 74, with 30 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 28% are also on Medicaid. Their average risk score is 4.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kelesidis' median patient age at 56, with 35% women.

In 2022, Dr. Kelesidis wrote 22 Medicare Part D claims. They cover 2 drugs, with $39,050 in total drug cost. In 2016, CMS named 20 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Kelesidis for performance year 2024, reported as part of a group. Dr. Kelesidis accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 145 papers to Dr. Kelesidis, published from 2005 to 2025. 2024 was the busiest year, with 7. The most frequent topics are Anti-Bacterial Agents, HIV Infections and Lipoproteins, HDL. Dr. Kelesidis has published most often in Am J Med. Dr. Kelesidis' most frequent co-authors are Iosif Kelesidis, MD, MS, Otto Orlean Yang, MD and Judith Silverstein Currier, MD.

Dmand AI links Dr. Kelesidis to 4 clinical trials, 2 of them phase 1/2 studies. 2 are still active or recruiting. Conditions studied include COVID-19, Acquired Immunodeficiency Syndrome and Lipid Metabolism Disorders. University of Texas Southwestern Medical Center sponsors the most, 3.

CMS Open Payments shows 4 general payments to Dr. Kelesidis from 2 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 83% of the total. Merck Sharp & Dohme Corporation paid the most, $91.

Dr. Kelesidis graduated from University of Athens in 2004.

Dr. Kelesidis is in network with 19 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Cigna. HMO plans come from the most carriers, 11. Check the plan with the practice before a visit.